Quantifying Uric Acid Excretion With RDEA3170, Febuxostat and Dapagliflozin
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2018
At a glance
- Drugs Dapagliflozin (Primary) ; Febuxostat (Primary) ; Verinurad (Primary)
- Indications Hyperuricaemia
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 11 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Jun 2018 Status has been changed to recruiting.
- 01 Jun 2018 Planned number of patients changed from 24 to 36.